Company Overview

Founded in June 2026, NovaLinko Bio Inc is a computational-first biopharmaceutical company focused on precision oncology and antiviral therapeutics. Headquartered in Burnaby, BC, we combine advanced in silico target discovery with rigorous experimental validation to build a pipeline targeting respiratory cancers, gastrointestinal cancers, melanoma, breast cancer, non-solid tumors, and hepatitis B virus (HBV).

Our differentiated approach begins with comprehensive dry-lab validation — molecular docking, target screening, and computational optimization — before committing to wet-lab execution. This de-risks early development, reduces capital burn, and creates a defensible IP position from day one.

Today, NovaLinko stands at the inflection point: dry-lab work is complete, wet-lab studies are underway, CDMO partnerships are being established, and intellectual property filings are in progress. We are actively seeking strategic investors and development partners to accelerate our path to IND.